Luciferase‐based quantification of membrane fusion induced by SARS‐CoV‐2 S protein
Luciferase‐based quantification of membrane fusion induced by SARS‐CoV‐2 S protein
复制标题
基于荧光素酶的 SARS-CoV-2 S 蛋白诱导膜融合定量
DOI：
10.1111/gtc.12945
复制
发表时间：
2022
期刊：
影响因子：
2.1
通讯作者：
Katayama Kazuhiko
中科院分区：
文献类型：
--
作者：
Haga Kei;Takai‐Todaka Reiko;Sawada Akihito;Katayama Kazuhiko
持续的COVID-19大流行由SARS-CoV-2引起。虽然已经部署了几种靶向病毒表面刺突蛋白的有效疫苗，但迫切需要其他治疗剂。在这里，我们开发了一个系统来测量刺突蛋白的功能，通过定量细胞膜融合诱导的刺突蛋白。该系统能够在不使用活病毒的情况下评估药物和中和抗体对SARS-CoV-2的影响。此外，该系统表征了每个变体的Spike蛋白的膜融合活性，以揭示Delta变体具有比Wuhan和Omicron更强的效力。我们的系统可以开发高通量筛选候选药物和中和抗体，靶向病毒进入并表征变体中的刺突蛋白。
The ongoing COVID‐19 pandemic is caused by SARS‐CoV‐2. Although several effective vaccines that target the Spike protein on the viral surface have been deployed, additional therapeutic agents are urgently needed. Here, we developed a system to measure the Spike protein function by quantifying cellular membrane fusion induced by the Spike protein. The system enables the evaluation of the effects of drugs and neutralizing antibodies against SARS‐CoV‐2 without using live viruses. Furthermore, the system characterizes membrane fusion activity of the Spike protein of each variant to reveal that Delta variant has more potent than Wuhan and Omicron. Our system could lead to develop high‐throughput screening for drug candidates and neutralization antibodies that target virus entry and characterize Spike proteins from variants.